Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06650833 alone · 1 trial · 1 indication
Maximum observed concentration (Cmax) derived from plasma
Area under the plasma concentration-time profile derived from plasma from time 0 to time tau, the dosing interval (AUCtau), where tau=24 for QD dosing.
Maximum observed concentration (Cmax) derived from plasma
Area under the plasma concentration-time profile derived from plasma from time 0 to time tau, the dosing interval (AUCtau), where tau=24 for QD dosing.
| Arm | Type | Description |
|---|---|---|
| Single arm | EXPERIMENTAL | The study will have only one study group in a fixed-sequence type of design with two periods |
| Name | Type | Description |
|---|---|---|
| PF-06650833 alone | DRUG | In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone. |
| PF-06651600 alone | DRUG | In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone. |
| PF-06650833 together with PF-06651600 | DRUG | In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily. |
Inclusion Criteria: * Male and female participants must be 18 to 55 years of age, inclusive, at the time of signing the informed consent document (ICD) * Male and female participants who are healthy as determined by medical evaluation including medical history, physical examination, including blood...
PF-06650833 is an investigational small molecule being studied in healthy participants. It is not approved for any disease and is in clinical development to assess its safety and interactions. The only completed trial evaluated it in healthy volunteers in the United States.
PF-06650833 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker PFE. The company sponsored the Phase 1 clinical trial of this investigational drug.
PF-06650833 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The single Phase 1 trial has been completed, and the drug is no longer in active clinical testing.
PF-06650833 has one completed Phase 1 trial, NCT03827668, titled "A Drug-Drug Interaction Study Between PF-06650833 and PF-06651600 Following Multiple Doses in Healthy Participants." The trial enrolled 15 healthy adults in the United States and was not randomized or blinded.
No, PF-06650833 and PF-06651600 are different investigational drugs. They were studied together in a drug-drug interaction trial, NCT03827668, to evaluate how they affect each other when given in multiple doses to healthy participants.